Thermo Fisher Scientific Inc. TMO recently announced a partnership with the National Cancer Institute (“NCI”) for the myeloMATCH (Molecular Analysis for Therapy Choice) precision medicine umbrella trial. Under the trial, patients’ bone marrow and blood will be tested for certain genetic biomarkers using Thermo Fisher’s next-generation sequencing (“NGS”) technology. With this, clinical sites can quickly match patients with an appropriate clinical trial that tests a treatment designed to target specific mutations present in the samples. The collaboration aims to accelerate research regarding new treatments for Acute Myeloid Leukemia (“AML”) and Myelodysplastic Syndrome (“MDS”). About myeloMATCH Trial Program myeloMATCH assembles a portfolio of sub-studies to treat patients with specific subtypes of AML and MDS through all stages of their treatment journey. Patient samples will be sequenced in the myeloMATCH Molecular Diagnostics Laboratory Network using the Ion Torrent Genexus System and reagents along with the Oncomine-based NCI Myeloid Assay to assign participants to myeloMATCH treatment studies. The Genexus system clinical teams across sites can quickly match eligible patients with the right trials to ultimately better understand the clinical impact of these therapies. Significance of the Partnership The trial aims at completing genomic testing and delivering complete results within a few days across testing modalities to help quickly enroll patients into specific sub-studies based on their biomarker profile at the time of diagnosis. Then, the first completely ready NGS solution will automate the specimen-to-report workflow design and deliver results within a day with just two user touchpoints. By conducting multiple treatment sub-studies specific to genomic types, the myeloMATCH trial will help accelerate the development of promising new therapies. Additionally, the NCI’s Division of Cancer Treatment and Diagnosis has developed cooperative research and development agreements with many pharmaceutical companies that will provide different drugs to support myeloMATCH trials. More on the News The myeloMATCH trial will be open in the U.S. and Canadian sites of the NCI National Clinical Trials Network, which includes more than 2,200 sites. Zacks Investment Research Image Source: Zacks Investment Research The myeloMATCH trial program, including the use of the Ion Torrent Genexus system and Oncomine technology for the NCI Myeloid Assay, has received Investigational Device Exemption and Investigational New Drug authorization from the FDA. Market Prospects Per a report from Mordor Intelligence, the NGS market is estimated at $10.47 billion in 2024 and is expected to reach $19.66 billion by 2029, witnessing a CAGR of 13.43% during the period. Primary factors, including the increasing applications in clinical diagnosis and speed, cost and accuracy, along with the enhanced efficiency when compared with traditional technologies such as microarrays and the rising number of drug discovery applications, are expected to accelerate market growth. Considering the market potential, TMO’s latest partnership for the myeloMATCH trialis strategically timed. Other Notable Developments In June 2024, the company was part of several developments, including the introduction of biobased films to help reduce climate impact in the manufacturing of therapies. The biobased films build on the company’s existing Aegis and CX film offerings that are widely used and validated by customers. Along with this, the company also launched Heracell VIOS 250i AxD CO2 Incubators to support the future implementation of workflow automation in cell therapy production. Additionally, Thermo Fisher opened a new clinical and commercial ultra-cold facility in the European Union , thereby expanding its clinical trial network in Europe to help accelerate the development of advanced therapies. Price Performance In the past year, TMO shares have risen 3.4% against the industry’s 4.9% decline. Zacks Rank and Other Key Picks Thermo Fisher currently carries a Zacks Rank #2 (Buy). Other top-ranked stocks in the broader medical space are Hims & Hers Health, Inc. HIMS, Medpace Holdings MEDP and Haemonetics HAE. While Hims & Hers Health and Haemonetics sport a Zacks Rank#1 (Strong Buy) each, Medpace carries a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank stocks here. The Hims & Hers Heath stock has surged 142.8% in the past year. Estimates for the company’s 2024 earnings have moved north 10% to 20 cents per share in the past 30 days. HIMS’ earnings beat estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 79.2%. In the last reported quarter, it posted an earnings surprise of 150%. Estimates for Medpace’s 2024 earnings per share (EPS) have remained unchanged at $11.29 in the past 30 days. Shares of the company have gained 79.9% in the past year compared with the industry’s 4.9% growth. MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 12.8%. In the last reported quarter, it delivered an earnings surprise of 30.6%. Estimates for Haemonetics’ 2024 EPS have increased 0.4% to $4.57 in the past 30 days. In the past year, shares of HAE have risen 4.4% against the industry’s 4.9% decline. In the last reported quarter, HAE delivered an earnings surprise of 2.27%. The company has a trailing four-quarter average earnings surprise of 13.24%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Thermo Fisher Scientific Inc. (TMO):Free Stock Analysis Report Haemonetics Corporation (HAE):Free Stock Analysis Report Medpace Holdings, Inc. (MEDP):Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Thermo Fisher (TMO) Inks New Partnership for myeloMATCH Trial
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...